Issue 124 • November 2022

Oncology therapies dominate the orphan drug landscape

Inflation drives manufacturing focus on sustainability

Urgent need to update Canada’s breast cancer screening guidelines

In association with

Medicine in outer space

With investment in space rising and humans on the cusp of travelling to Mars, new tools are being developed to test and manufacture medicines beyond our planet

In association with

Issue 124

Brought to you by

02/23/2024 23:28:23
  • Home | Medicine in outer space
  • In this issue
  • Contents
  • CSafeAPS
  • Agilent
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Pfeiffer Vacuum
  • Mimotopes Company Insight
  • Mimotopes
  • Allpack group ag
  • Comment
  • Sandoz spin-off continues Novartis’ focus on innovation
  • High risk, high reward – the future of CAR-T therapy in CLL
  • bluebird bio bags landmark FDA approvals for gene therapies
  • Covid-19 vaccine companies boosted with over 80% revenue growth
  • Urgent need to update Canada’s breast cancer screening guidelines
  • The epidemiology of RSV changed in UK children during the pandemic
  • Zenatek Company Insight
  • BEA Technologies
  • In Depth
  • Medicine in outer space: drug development, manufacturing, and beyond
  • Oncology therapies dominate the orphan drug landscape
  • How environmental factors could influence disease and drugs
  • Joining the dots: How gene regulatory network tools are unearthing drugs
  • Inflation drives pharma manufacturing focus on sustainability
  • What do remote assessments mean for sponsors?
  • CMO Moves: Regulatory catalysts for drug manufacturing-October
  • Tripletree
  • In Data
  • Data analytics hiring levels in the pharma industry fell to a year-low in August
  • Pharma found it easier to fill cloud vacancies in Q2 of 2022
  • Pharma filings see a 56% increase in big data mentions since Q2 of 2021
  • Industrial automation hiring levels in pharma rose in August 2022
  • Events
  • Next issue
10/20/2022 00:00:00